Physician profile
Andrea Brown
NPI 1972509420
$3,793.78
in general payments reported to CMS, 2019-2025
27 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $335 · 2021: $560 · 2022: $14.56 · 2023: $37.27 · 2024: $1,247 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $918.17 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $695.23 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $393.96 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $321.89 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $244.24 | 2023-2025 | |
| Pfizer INC. | $226.39 | 2021-2024 | |
| Allergan, INC. | $181.08 | 2019-2020 | |
| Exact Sciences Corporation | $146.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Scilex Pharmaceuticals INC. | $72.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.84 | 2020 | |
| Gilead Sciences, INC. | $69.18 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.21 | 2021 | |
| Abbvie INC. | $55.31 | 2021 | |
| Inspire Medical Systems, INC. | $50.32 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $38.11 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $29.47 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $23.80 | 2025 | Neffy |
| Xeris Pharmaceuticals, INC. | $23.65 | 2021 | |
| Hologic Sales and Service, LLC | $22.52 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.11 | 2025 | Uptravi, Opsumit |
| Dynavax Technologies Corporation | $21.98 | 2024 | Heplisav-B |
| Eisai INC. | $20.67 | 2021 | |
| Dexcom, INC. | $20.31 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $18.14 | 2024 | Otezla, Repatha |
| Conmed Corporation | $17.95 | 2025 | Visiclear, Airseal, Abc Handpieces |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.01 | 2020 | |
| Merck Sharp & Dohme LLC | $14.66 | 2025 | Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.